TP Therapeutics Revenue and Competitors

Claim your profile

Location

#5874

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • TP Therapeutics's estimated annual revenue is currently $30.8M per year.(i)
  • TP Therapeutics received $80.0M in venture funding in October 2018.
  • TP Therapeutics's estimated revenue per employee is $102,425
  • TP Therapeutics's total funding is $1.2B.
  • TP Therapeutics's current valuation is $1.9B. (January 2022)

Employee Data

  • TP Therapeutics has 301 Employees.(i)
  • TP Therapeutics grew their employee count by 25% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

TP Therapeutics, Inc. (TP) is a clinical-stage structure-based drug design company for the discovery and development of precision medicines for cancer and other diseases. We are focusing on the design of novel chemical identities for established oncogene drivers with secondary resistant mutations, newly identified disease-driven targets, and potential targets regulating tumor microenvironment and tumor immunity. Our lead therapeutic project, TPX-0005, is in clinical development (TRIDENT-1). TP- Turning Point Medicines for Life!

keywords:Biotechnology,Healthcare,Pharmaceuticals

$1.2B

Total Funding

301

Number of Employees

$30.8M

Revenue (est)

25%

Employee Growth %

$1.9B

Valuation

N/A

Accelerator

TP Therapeutics News

2022-04-19 - Tarsus Presents Results of Two Studies Highlighting Demodex ...

About TP-03 TP-03 (lotilaner ophthalmic solution, 0.25%) is a novel, investigational therapeutic designed to resolve the signs of Demodex...

2022-03-30 - Axsome: A Speculative Buy, Undervalued Biotech With A Short-Term Catalyst

We are initiating coverage of Axsome Therapeutics with a BUY rating, TP of 120 USD. · Our enthusiasm revolves around the April 29th PDUFA for AXS...

2022-03-30 - Sumitomo Pharma Oncology Presents New Data from ...

... Pipeline of Novel Cancer Therapeutics at AACR Annual Meeting 2022 ... TP-1287 is an investigational oral CDK9 inhibitor that has shown...

2019-09-11 - Turning Point Therapeutics Raises $202.5M in Follow-On Offering

After raising $175.2 million in an initial public offering this spring, Turning Point Therapeutics has returned to the public market. The cancer drug developer on Sept. 10 raised $202.5 million in a follow-on offering. Turning Point sold 4.5 million shares of common stock at a price of $45 a sh ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$92.2M30113%N/A
#2
$102.6M30424%N/A
#3
$47.1M304-3%N/A
#4
$49.9M30716%N/A
#5
$105M3114%N/A

TP Therapeutics Funding

DateAmountRoundLead InvestorsReference
2014-01-10$1.4MUndisclosedArticle
2016-03-23$18.0MUndisclosedArticle
2017-05-24$45.0MCLilly Asia VenturesArticle
2018-10-22$80.0MUndisclosedForesite CapitalArticle